These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28219003)

  • 1. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.
    Cho BS; Kim HJ; Konopleva M
    Korean J Intern Med; 2017 Mar; 32(2):248-257. PubMed ID: 28219003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
    Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
    Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
    Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH
    Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?
    Tavor S; Petit I
    Semin Cancer Biol; 2010 Jun; 20(3):178-85. PubMed ID: 20637871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?
    Bernasconi P; Farina M; Boni M; Dambruoso I; Calvello C
    Am J Hematol; 2016 May; 91(5):507-17. PubMed ID: 26822317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CXCR4 in the pathogenesis of acute myeloid leukemia.
    Peled A; Tavor S
    Theranostics; 2013; 3(1):34-9. PubMed ID: 23382784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
    Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M
    PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
    Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M
    Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo.
    Li X; Guo H; Yang Y; Meng J; Liu J; Wang C; Xu H
    Sci Rep; 2014 Oct; 4():6610. PubMed ID: 25312253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
    Peled A; Klein S; Beider K; Burger JA; Abraham M
    Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the microenvironment in acute myeloid leukemia.
    Rashidi A; Uy GL
    Curr Hematol Malig Rep; 2015 Jun; 10(2):126-31. PubMed ID: 25921388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
    Zeng Z; Samudio IJ; Munsell M; An J; Huang Z; Estey E; Andreeff M; Konopleva M
    Mol Cancer Ther; 2006 Dec; 5(12):3113-21. PubMed ID: 17172414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
    Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
    Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CXCR4: a new therapeutic target of the leukaemic cell? Role of the SDF-1/CXCR4 axis in acute myeloid leukaemia].
    Tavernier E; Aanei C; Solly F; Flandrin-Gresta P; Campos L; Guyotat D
    Bull Cancer; 2014 Jun; 101(6):593-604. PubMed ID: 24977448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia.
    Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H
    J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
    Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
    Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.
    Zhang Y; Patel S; Abdelouahab H; Wittner M; Willekens C; Shen S; Betems A; Joulin V; Opolon P; Bawa O; Pasquier F; Ito M; Fujii N; Gonin P; Solary E; Vainchenker W; Coppo P; De Botton S; Louache F
    Cell Death Dis; 2012 Oct; 3(10):e396. PubMed ID: 23034331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
    Sison EA; McIntyre E; Magoon D; Brown P
    Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia.
    Ramakrishnan R; Peña-Martínez P; Agarwal P; Rodriguez-Zabala M; Chapellier M; Högberg C; Eriksson M; Yudovich D; Shah M; Ehinger M; Nilsson B; Larsson J; Hagström-Andersson A; Ebert BL; Bhatia R; Järås M
    Cell Rep; 2020 May; 31(8):107684. PubMed ID: 32460032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.
    Burger JA; Peled A
    Leukemia; 2009 Jan; 23(1):43-52. PubMed ID: 18987663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.